At a glance
- Originator Bristol-Myers Squibb
- Developer BTG
- Class Antihypotensives; Cardiotonics
- Mechanism of Action Alpha 1 adrenergic receptor antagonists; Calcium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation